XRCC6 and neoplasm: Consistently, c-olaparib and c-rucaparib pull downs using frozen BRCA1-deficient OC tumor samples in comparison with BRCA1-proficient OC tumor samples, also showed increased enrichment of Ku70/Ku80 in BRCA1-deficient samples (Figs. 2E and S1C).